Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Treat Rev. 2011 Nov;37(7):533-42. doi: 10.1016/j.ctrv.2010.11.004. Epub 2010 Dec 22.

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

Author information

  • 1Cancer Biology Proteomics Group, Postgraduate Medical Institute of the University of Hull and Hull York Medical School, Hull, UK.


The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients.

Copyright © 2010 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk